Filing Flows › Mangoceuticals (MGRX) › Q2 2026 › vs Q1 2026
Mangoceuticals (MGRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Mangoceuticals's revenue rose $1K (+1%) from $68K in Q1 2026 to $69K in Q2 2026.
Mangoceuticals, Q2 2026: revenue $69K (-59% year over year), net loss $1.3M, operating cash flow −$261K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $69K | $68K | $1K | +1% |
| Net loss | $1.3M | $3.4M | −$2.1M | -61% |
| Costs & expenses | $1.4M | $3.5M | −$2.1M | -60% |
| Operating costs | $1.1M | $3.2M | −$2.1M | -66% |
| Interest & other, net | $280K | $277K | $3K | +1% |
| Cost of revenue | $25K | $39K | −$14K | -37% |
| Sales & marketing | $301K | $94K | $207K | +220% |
| General & admin | $256K | $1.1M | −$798K | -76% |
| Other operating costs | $520K | $2.0M | −$1.5M | -74% |
| Operating cash sources | $1.3M | $3.4M | −$2.1M | -61% |
| Depreciation & amortization | $280K | $277K | $3K | +1% |
| Share-based compensation | $12K | $1.1M | −$1.1M | -99% |
| Working capital & other | $760K | $725K | $35K | +5% |
| Cash used in operations | $261K | $1.3M | −$1.1M | -80% |
| Net loss absorbed | $1.3M | $3.4M | −$2.1M | -61% |
Questions
How much did Mangoceuticals's revenue grow quarter over quarter in Q2 2026?
Mangoceuticals's revenue rose $1K (+1%) from $68K in Q1 2026 to $69K in Q2 2026.